Britain's genomics landscape and 10 exciting businesses to watch

Britain is a major player in the global genomics field. With a rich history of scientific discoveries, the genomics sector in the UK continues to grow. In this article, we take a look at how and where innovation and growth is occurring for the British genomics industry and take a deeper look into 10 exciting businesses that are taking the sector by storm.

Investment in British genomics

As the name implies, genomics is the study of genomes, the complete set of genes or genetic material in a cell or an organism. As almost every cell in the human body contains a complete copy of the genome, which contains all the information needed for development and growth, studying genomes can help with understanding how genes interact with one another and the environment, and how certain diseases (such as cancer, diabetes, and heart disease) form. In turn, new ways to diagnose, treat, and prevent diseases like these are developed.

From the discovery of the double helix structure of DNA by British scientists studying at King’s College in the 1950’s, to Fred Sanger’s development of DNA sequencing in the 1970’s, the UK has long been viewed as a leader in the world of genomics development. With developments in the sector continue to gather pace, we take a look into the dynamic world of the UK genomics sector and highlight 10 innovative and interesting UK companies that are contributing to its commercial development.

Besides historic scientific discoveries in the field, the UK’s leading position in genomics can be contributed to a number of factors. In no particular order, the UK offers particularly attractive tax reliefs to innovative businesses such as R&D tax credits, and the Enterprise and Seed Enterprise Investment Schemes (EIS and SEIS respectively). These reliefs make the UK a particularly attractive location for talented scientists looking to research and develop innovative drugs and technologies in the space. Secondly, the contributions of the NHS cannot be forgotten; the NHS provide the ability to link a lifetime of medical records with a person’s genome data on a large scale, which furthers the understanding of diseases and provides insight into the complex relationship between genes, the surrounding environment, and illness. Cementing the UK’s position as the world leader in genomics are various initiatives including the following:

100,000 Genome Project’s seeking to sequence and study the role of genes in health and disease,
The UK Biobank, a large-scale biomedical database and research resource, and
The NHS Genomics Medicine Service, who are driving to deliver a single national testing directory covering use of all genomic technologies, and to build a national genomic knowledge base that will provide real world data to inform both academic and industry R&D.

In order to understand how the UK is driving innovation and commercial growth in the genomics field, we used data from Beauhurst to understand the landscape of the sector and understand where investment is taking place.

Fundraising activity of companies in the UK genomics sector

Fundraising activity over the past 10 years for UK genomics businesses

*Beauhurst

The highest peak in total fundraising raised was seen in 2021, an increase of 86% on the previous year and an immediate decrease of 51% in the following year. As we have seen previously, 2021 was a good fundraising year across different sectors. The preceding years saw fundraising levels around what was seen pre-pandemic. The number of fundraisings has remained fairly consistent over this time period, being on average 17% below the numbers seen pre-pandemic.

Characteristics of UK genomics companies

Current stage of evolution for UK genomics businesses

*Beauhurst

Over half of UK genomics companies are in the early start-up stages, seed and venture. This reflects the relative infancy of the sector, with nearly two-thirds of companies incorporating within the past ten years. There is positive progress as, compared to our last report in 2024, the proportion of companies in the established stage has doubled.

There have been 60 exits amongst these companies, with around two-thirds being acquisitions and the remaining third being IPOs. The average acquisition price is £189m, while for IPOs it is £332m.

*Beauhurst

The top 5 sectors are not all that surprising; they are what is expected given the nature of the work that is conducted in the genomics sector. Pharmaceuticals, biotechnology, and clinical research are clear focuses of the sector. By looking at the top buzzwords for these sectors, we can see if there are any additional focuses for genomics businesses that would not be captured otherwise. There is an inclination towards the technology side, with a focus on AI.

Company profiles

We now place the spotlight on 10 exciting genomics businesses.

Touchlight

Evolution: Growth

Fundraising:

£25k equity investment in 2010 for a 0.9% stake.
£1.04m equity investment in 2011 for a 23% stake.
£4.15m equity investment in 2013 for a 18% stake.
£1.02m equity investment in 2014 for a 4% stake. Investors included Downing.
£3.19m equity investment in 2015 for a 9% stake.
£2.34m equity investment in 2016 for a 4% stake.
£2.23m equity investment in 2017 for a 3% stake.
£15k equity investment in 2018 for a less than 0.1% stake.
£42.1m equity investment in 2021 for a 9% stake. Investors included Bridford Group.
£87.2m equity investment in 2021 for a 15% stake. Investors included Bridford Group and Novator Partners.

Grants:

£132k grant awarded in 2011.
£108k grant awarded in 2012 by Innovate UK.
£95.9k grant awarded in 2014 by Innovate UK.
£89.7k grant awarded in 2016 by Innovate UK.
£141k grant awarded in 2017 by Innovate UK.
£269k grant awarded in 2018 by Innovate UK.
£16.2k grant awarded in 2022 by Innovate UK.
£14m grant awarded in 2023 by Life Sciences Innovative Manufacturing Fund (LSIMF).
£767k grant awarded in 2023 by Innovate UK.
£268k grant awarded in 2024 by Innovate UK.

Industries: Biotechnology, Clinical research, Pharmaceuticals

Buzzwords: Genomics, Life science, Professional and business services

Touchlight, who are leading the industrialisation of cell-free DNA and its application in genetic medicines, were founded by Jonny Oslen in 2007. He witness the immense potential of genetic medicine in transforming human health but concluded that for it to fully realise that potential, a better way to make DNA was needed. Hence why Touchlight was founded, a platform free from the constraints of bacterial fermentation, with faster timelines, cleaner products, and scalable solutions fit for the most advanced therapies. Their founder has been the board director at Saatchi and Saatchi Advertising Ltd, Managing Director of Griffin Bacal Advertising, Chairman of the Institute of Practitioners in Advertising Society, and the main board director of Soho House Ltd. In addition to Touchlight, he has founded the UK distribution company One Squared Ltd and registered charity The Reconstruction Project.

They have three main technological offerings:

Doggybone™ DNA (dbDNA™): Touchlight’s proprietary enzymatic DNA technology and the next-generation DNA template for genetic medicines. With it being a cell-free alternative to plasmid DNA and not having the same limitation of bacterial fermentation, it is designed to accelerate the development of genetic therapies by enabling rapid, scalable, and high-purity DNA production. It is able to power a range of programmes, including non-viral gene therapies, RNA, viral vectors, gene editing, and DNA vaccines.
z- dbDNA™: By enabling rapid and flexible RNA development and facilitating the scale-up to GMP production without needing a Master Cell Bank, it has marked itself as the next-generation DNA template for in vitro transcription (IVT). It delivers a high purity IVT template with optimal performance and quality attributes, meaning that timelines are sped up and the number of bottlenecks is reduced in bringing mRNA-based therapies to the clinic.
mbDNA™ and Custom Circles: This is their suite of novel circular DNA architectures which are able to enhance gene therapy technologies and overcome CRISPR HDR’s reliance on dividing cells. Each format supports a range of genetic engineering applications thanks to their user-defined sequences and structural flexibility. The offerings available through the platform are compatible with various editing technologies, such as HDR, homology-independent targeted integration (HITI), recombination, and transposition. Included is:
- mbDNA™, a double-stranded stem that has a single-stranded circular bulb, is optimised as a payload template for homology-directed repair (HDR).
- sscDNA is a fully single-stranded circular DNA structure.
- hsscDNA design is predominantly a single-stranded molecule, so that the benefits of ssDNA are retained, that also has strategically placed double-stranded regions.
- dscDNA is a fully double-stranded circular DNA module that has a completely user-defined sequence.

Touchlight have had a remarkable year. They kicked off 2025 with their facility in Hampton, UK receiving GMP certification, becoming the first synthetic DNA manufacturer in the world to achieve regulatory approval to produce Active Pharmaceutical Ingredient (API). The certification will allow Touchlight to support its growing customer base with developing DNA vaccines and non-viral gene therapies. Around the same time, Ceva Animal Health was granted the rights to use Touchlight’s dbDNA technology to develop and manufacture future products across the animal health field.

During this year, their Morelands Facility was named the 2025 Innovation Winner at the prestigious International Society for Pharmaceutical Engineering (ISPE) Facility of the Year Awards (FOYA).

In the middle of last year, they announced the commercial launch of their mbDNA™ (megabulb DNA), a new technology for non-viral gene editing. With its novel circular single-stranded DNA (ssDNA) structure, it features a customisable stem region and a fully user-defined sequence free of phage or bacterial elements. Thanks to its design, it is able to support 1-20kb gene insertions and offer more robust knock-in efficiency across diverse cell types than double-stranded DNA (dsDNA) and competitor ssDNA formats without losing high cell viability. At the end of the year, they then announced the expansion of their mbDNA™ platform by introducing three new circular DNA architectures in the form of sscDNA, hsscDNA, and dscDNA.

Already in 2026, they have entered into a collaboration with New England Biolabs (NEB®). The result of the partnership is the EnClose™ Cell-free dbDNA™ Synthesis Kit, which is a new benchtop solution that allows for rapid enzymatic production of Touchlight’s dbDNA™. The kit integrates NEB’s enzymatic expertise with Touchlight’s dbDNA platform, allowing for a streamlined workflow so that researchers can generate high yields of closed-ended DNA in a single day.

They have also announced a strategic partnership with SVF Vaccines, where they will work together to progress SVF’s Hepatitis B/D vaccine into clinical development. The vaccine is designed to target essential viral components for both Hepatitis B (HBV) and Hepatitis D (HDV) viruses, in particular the PreS1 region and the HDV large antigen, hence stimulating the neutralising antibody responses and activating the T-cell responses to eliminate infected cells. Touchlight’s dbDNA™ platform has the capability for dose sparing, which has the potential to deliver effective immunity at substantially lower doses compared to pDNA. This partnership is a significant move towards addressing HBV and HDV, both of which affect millions around the world, by using the power of advanced vaccine technologies.

T-Therapeutics

Evolution: Seed

Fundraising:

£30m equity investment in 2023 for a 59% stake. Investors included Cambridge Enterprise Ventures, Cambridge Innovation Capital (CIC), Digitalis Ventures, F-Prime Capital Partners, Sanofi Ventures, Sofinnova Capital, and University of Cambridge Venture Fund.
£38.2m equity investment in 2025 for a 51% stake. Investors included BGF, CIC, Digitalis Ventures, F-Prime Capital Partners, Sanofi Ventures, Sofinnova Capital, Tencent, and University of Cambridge Venture Fund.

Industries: Pharmaceuticals, Research tools and reagents

Buzzwords: Genomics, Life sciences, Precision medicine

T-Therapeutics, a University of Cambridge spinout, is a next-generation T cell receptor (TCR) company. They were founded in 2022 by CSO Professor Allan Bradley, who is a professor in the University of Cambridge’s Department of Medicine and is well-known for his role in the development of ES cell technology while he was a graduate student at Cambridge. This work was acknowledged when his thesis advisor, Martin Evan, received a 2007 Nobel Prize.

Their mission is to create safe, effective treatments for different types of cancer and autoimmune diseases by harnessing the power of T cell biology. T cells, which are a type of white blood cells, play an important role in the immune system, specifically for immunity of foreign substances by circulating until they find their specific antigen and attack it. The TCR is the part of the T cell that binds to a foreign antigen or cancer neoantigen, causing the activation, proliferation, and differentiation of the T cell. By utilising everything explained here, T-Therapeutics is developing drugs that can identify the cancer specific self-antigens to then direct T cells to exterminate these cancer cells.

Their proprietary OpTiMus^TM platform, which is based on a fully humanised TCR mouse able to provide a nearly unlimited source of unique, antigen-specific human TCRs, is how they are developing optimal TCR based therapeutics. It is a highly engineered transgenic mouse that carries genes for the human immune system. By immunising the mouse with human peptides, it is able to make humanised TCRs that do not exist in the human repertoire, providing an almost unlimited supply of TCRs with unique properties such as diversity, activity, half-life, and affinity.

These TCRs allow for T-Therapeutics to develop their next generation of transformative medicines that are designed to target specific disease markers, starting with those found in cancer and, in time, those in autoimmune and infectious diseases. They can bind strongly to cancer-specific targets and help the immune system in targeting the tumour issues and in destroying them. By applying machine learning, only the most active molecules are selected and used as building blocks in making T-Therapeutics’ first-in-class and best-in-class drug candidates.

At the end of last year, they announced the expansion of their Series A financing, raising an additional $32m on top of the $59m initially raised. Joining the Series A syndicate as new investors are Tencent and BGF, alongside the existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, and the University of Cambridge Venture Fund. The purpose of this funding is to drive their pipeline of first-in-class TCR-CD3 bispecifics across oncology and autoimmune diseases towards the clinic as well as exploring further new therapeutic strategies like T cell subset depletion.

Shift Bioscience

Evolution: Venture

Fundraising:

£250k equity investment in 2017 for a 17% stake. Investors included Meltwind Advisory.
£125k equity investment in 2018 for a 3% stake.
£100k equity investment in 2019 for a 2% stake.
£3.97m equity investment in 2021 for a 30% stake.
£949k equity investment in 2022 for a 6% stake.
£8.59m equity investment in 2024 for a 35% stake. Investors included BGF, Business Angels, F-Prime Capital Partners, and Kindred Capital.

Grants:

£10k grant awarded in 2019 by Accelerate@Babraham.
£350k grant awarded in 2023 by Innovate UK.
£348k grant awarded in 2025 by Innovate UK.

Industries: Biotechnology, Clinical research, Pharmaceuticals

Buzzwords: Artificial Intelligence, Digital and technologies, Genomics, Life sciences, Professional and business services, Regenerative medicine

Cambridge based Shift Bioscience, referred to as Shift, is on a mission to reverse aging through cell rejuvenation, where cell age is reduced safely without changing cell identity. They were founded in 2017 by Dr Daniel Ives (CEO) and Dr Brendan Swain (CSO). Dr Daniel Ives achieved his PhD at the University of Cambridge, discovering a novel therapeutic approach for a rare mitochondrial disease through his work on harnessing computational biology. This discovery of his has led him from the adoption of mouse aging clocks, to validating therapeutic hypotheses, to single-cell aging clocks and ending with AI-powered virtual cells that can maximise the experimental throughput of single-cell aging clocks. Dr Brendan Swain also achieved his PhD at the University of Cambridge, but his work focused on membrane transporter proteins in charge of removing chemotherapy drugs from cancer cells as well as antibiotics from bacteria. From here, he became the pioneer behind the first accurate single-cell aging clock and his work at Shift has seen the development of single-cell aging clock models for human cells.

The team at Shift are developing an AI-driven pipeline of therapeutic candidates for conventional indications that have defined regulatory paths, which have been validated for cellular age reversal. Their approach is partially based on epigenetic clocks, the validated biomarkers of aging. They come from research by Steve Horath who proved that specific methylation sites, the pattern on genomic DNA that changes in a conserved way as organisms age, can be used to accurately predict the chronological age across most tissues residing in the human body. They have since become the most widely used aging biomarker in the field, having close to 7,000 citations.

The science behind Shift’s pipeline also brings in the Yamanaka factors (OSKM). They are a group of four genes that can rejuvenate the epigenetic clock in multiple types of cells and have been proven to extend the lifespan of mouse models. However, as this gene combination activates a tumour-inducing pluripotency pathway, it cannot be translated into a rejuvenation therapeutic. Researchers found that by omitting oncogene C-Myc from OSKM, hence reducing it to OSK, the remaining lifespan of already aged mice could be doubled. While the therapeutic window of OSK remains unclear due to its pluripotency legacy, it has now been moved to clinical trial for restoring age-linked vision loss.

By utilising the science and research above, Shift have developed a next-generation discovery platform centred around two large-scale property datasets. The first being a multiomic observational dataset that facilitates the training of their high throughput single cell aging clock (AC3), which is highly correlated with validated DNAm aging clocks. The second is an scRNAseq perturbation dataset, which is used for training virtual cell models. Shift has used these datasets to train machine learning tools so that they can identify promising targets for cell rejuvenation with high speed and precision, condensing centuries of real-world experiments into only months of work. Their platform to date has identified more than 190 genes, with 150 able to reverse cellular aging and 40 that can do the reverse.

Shift has two featured discoveries:

SB000: A rejuvenation gene, discovered by Shift in 2025, that is able to rejuvenate epigenetic clocks across cell types by three to ten years per month of over-expression. As a gene therapy, it has the potential to address a wide range of indications, such as age-related hearing and vision loss.
SB101: A pro-aging gene which is expressed through the body. As proven by Shift, SB101 siRNA can reverse epigenetic age across cell types by 1 year per month while preventing fibrosis. The gene can be utilised to address age driven fibrotic diseases, like liver fibrosis and systemic sclerosis, through inhibition by siRNA or small molecule.

At the start of 2025, they announced the establishment of a North American team and facilities based in Toronto, Canada, helping to advance the development of their platform. They will gain access to top machine learning talent, strengthening their IP portfolio and developing new capabilities for their virtual cell platform.

In the middle of the same year, they released the results of their study on an improved approach to ranking virtual cell models for gene discovery. Led by Lucas Paulo de Lima Camillo, the Head of Machine Learning at Shift, the study used both virtual cell and real-world data to show how true model performance gets misrepresented when using commonly used metrics thanks to experimental factors, like control bias and weak perturbations. From here, the team worked together to develop a series of steps designed to better rank models while driving focus towards more biologically meaningful changes. Included in these steps are differentially expressed gene (DEG)-weighted score metrics, negative and positive baseline calibrations, and DEG-aware optimisation objectives. Hence, they have created an improved framework for developing more powerful virtual cell models which will help Shift to accelerate their own rejuvenation target discovery pipeline.

Nearer the end of the year, their new research on an improved framework for evaluating benchmark metric calibration in virtual cell models was released. The team built upon their finding that demonstrated that incidents of poor model performance are mostly due to metric miscalibration, as the most commonly used metric often fail to separate robust predictions from uninformative ones, especially when the dataset has weaker perturbations. They identified several well-calibrated rank-based and DEG (Differentially Expressed Gene)-aware metrics with the use of 14 perturb-seq datasets. They successfully proved that the virtual cell models evaluated using these metrics consistently outperformed uninformative mean, control, and linear baselines, showing that virtual cell models are able to distinguish biologically significant signals when appropriate calibration is applied. This research opposes prior reports which state that genetic perturbation models do not work. It also implies that AI Virtual Cells can be effectively applied for target discovery.

Moa Technology

Evolution: Venture

Fundraising:

£340k equity investment in 2017 for a 10% stake. Investors included the University of Oxford Innovation Fund (UOIF).
£6.35m equity investment in 2019 for a 53% stake. Investors included Oxford Science Enterprises, and Parkwalk Opportunities EIS Fund.
£4.98m equity investment in 2021 for a 26% stake. Investors included BGF, Bits x Bites, and Parkwalk Opportunities EIS Fund.
£35m equity investment in 2022 for a 45% stake. Investors included BGF, Bits x Bites, IP Group, Knowledge Intensive EIS Fund, Lansdowne Partners, Oxford Science Enterprises, Parkwalk Opportunities EIS Fund, and the University of Oxford.

Grants:

£124k grant awarded in 2023 by Innovate UK.

Industries: Agriculture, land farming and forestry, Biotechnology, and Food and drink processing

Buzzwords: Genomics, Life sciences

One of TIME’s Top Greentech Companies in 2025, Moa Technology, based on the Oxford Science Park, is a spin out of the University of Oxford. They were founded in 2017 by Professor Liam Dolan and Dr Clément Champion, who at the time were researchers in the University’s Botany department. With their world-class team of scientists and industry experts, they want to create a future where crop yields are resilient by reinventing how synthetic and biological herbicides are discovered.

They get their name from something known as mode of action, or Moa, which simply means a way of working. In agriculture, a herbicide will work in a very different way to other herbicides when they have a new mode of action, meaning that the way in which the plant behaves, including at the cellular level, will fundamentally change. The problem that has occurred in the agricultural industry for half a century is that, as a small number of Moas are used repeatedly, weeds have an easier time adapting and developing resistance to them until they eventually stop working.

Moa Technology set out to find a different approach by reimagining the way in which herbicides, both synthetic and bio-herbicidal, are created. This led them to creating their proprietary screening platform called GALAXY, which is hosted in their Oxford labs. By testing up to 25,000 compounds a month on tiny living plants and using AI, machine learning, and their own databank, it is able to discover which compounds are effective and can create a novel mode of action in a matter of days. Herbicide candidates that have received successful lab validation move to their North Yorkshire research facility to undergo tests in different concentrations on a variety of weed and crop species, in both glasshouse and polytunnel environments. For the refinement and improvement of the compound’s design, data is sent back to their chemistry teams based in Oxford.

Before they can go to market, candidates have to go through several more steps. They have to undergo field trials, where they are subjected to real-world conditions and exposed to different combinations of climates, soils, crops, and weed species. From here, they are optimised in the lab in line with the data generated by lab tests and these trials. The potency and formulation of each candidate is refined and adjusted so that the final project is affordable, effective, and safe for the environment, wildlife, and human beings. The last stage before market involves longer global trials which verify that the candidates are safe and ready to use.

In the previous four years, they have discovered around 80 new modes of action, creating a generation of different herbicides that can assist farmers in controlling weeds more effectively while having a reduced impact on the environment. By having a wide range of options that work in various ways, single modes of action are less likely to be over-used, circumventing the issue of weeds developing new resistances.

Announced last year was their partnership with an Italian natural products company named NAICONS. From NAICONS’ library of natural products, 70,000 micro-bacterial extracts will be rapidly tested by Moa Technology’s screen platform in search of biological leads with the potential to control weeds without negatively impacting human life or the environment. These leads could either be a new herbicide or be used to improve the efficacy, safety, and resistance-breaking potential of existing herbicides. As part of the agreement, Moa Technology has exclusive rights to develop any new herbicides discovered during this process, but any value from future licensing and commercialisation will be shared.

Later in the year, they announced their discovery of a new class of novel amplifier molecules. While they are non-herbicidal on their own, they have the potential to reduce the amount or concentration of the agricultural herbicides farmers are currently using. Gowan Company, a leading US agricultural solutions business, is the first collaboration partner for this new category of products, providing a significant investment that includes upfront payments and future value creation sharing through milestone payments and royalties. At the time of the announcement, a Moa technology amplifier was in pilot field trials in Australia where the ways in which it can help to reduce herbicide use rates were being evaluated against annual ryegrass, an extremely tough and hard to control weed that causes a lot of damage. In the UK, other amplifier pilot field trials with cereal grassweeds were underway.

In the same year, they announced the next stage of their collaboration with Nufarm, a global crop protection and seed technologies company, which will see a novel mode of action agricultural herbicide brought to the global market over a year earlier than usual. In just twelve months, the initial research phase has already been completed. The next phase involves larger global field trials, crop use and safety studies, human and environmental safety testing, and the optimisation of the product for commercial use. As per the deal, Nufarm have been given exclusive access to a compound in one of Moa Technology’s novel mode of action chemical classes and will retain an exclusive first option to commercialise their other compounds as long as they are from the same mode of action. On the other hand, Moa Technology will receive upfront payments, milestone development payments, and royalties from the sales of the herbicide.

At the beginning of this year, they announced a strategic collaboration with Certis Belchim, a force in crop protection with strong foundations, surrounding the development of next-generation herbicide Moa Amplifier TM solutions for agriculture worldwide. By bringing together Moa Technology’s discovery platforms and Certis Belchim’s great expertise in product development, registration, and marketing for worldwide sustainable crop protection, they are working together to develop a novel Moa amplifier molecule for a specific active ingredient.

Relation Therapeutics

Evolution: Growth

Fundraising:

£1.15m equity investment in 2021 for a 10% stake.
£20m equity investment in 2022. Investors included DCVC, Firstminute Capital, Khosla Ventures, Magnetic Ventures, OMERS Ventures, and Business Angels.
£27.5m equity investment in 2024. Investors included ARK Invest, DCVC, Deerfield Management, Khosla Ventures, Magnetic Ventures, NVentures, and Business Angels.
£19.5m equity investment in 2025. Investors included DCVC, Magnetic Ventures, and Novartis.

Grants:

£973k grant awarded in 2020 by The Bill & Melinda Gates Foundation.

Industries: Biotechnology, Clinical research, Data provision and analysis, Pharmaceuticals, Research tools and reagents

Buzzwords: Artificial Intelligence, Digital and technologies, Genomics, Life sciences, Precision medicine, Professional and business services

Relation, an end-to-end biotech company focusing on the development of transformational medicine, was founded at the start of 2020 by Charles Roberts (Chairperson), Benjamin Swerner (COO), and Jake Taylor-King (CIO). Charles Roberts, a medically trained serial biotech entrepreneur, is also the Chief Investment Strategist at ARK where he leads the ARK VC team and sits on the Investment Committee for the ARK Venture Fund as well as the ARK’s public-private crossover fund. Benjamin Swerner before Relation worked at one of Europe’s oldest venture firms, DN capital. When he was there, his work focused on investment into healthcare and deep-tech. Before the creation of Relation, Jake Taylor-King was the Head of Bioinformatics at Empyrean Therapeutics where he worked on designing and optimising high throughput CRISPR screens. He is also the recipient of the G-Research prize and the Lee Segel Prize.

Relation are creating experimental and computational systems that aide in the understanding of the biological processes involved with human health and disease. They facilitate the generation, analysis, and interpretation of human data, including the behaviour of genes, cells, and tissues. This allows for the team at Relation to identify new therapeutic targets and then translate them into transformational medicines. Their approach is called Lab-in-the-Loop, a system that allows for the integration of single-cell analysis, genomics, and machine learning. It is primarily made up of four parts:

Multi-modal patient data: By using human genetics and proprietary omics which have been directly generated from patient tissue, they are building an understanding of the genetic basis of clinical phenotypes. They are creating detailed maps of disease biology that allow them to discover novel targets. Through this data, they can link cause to phenotype which they then test with perturbational omics and translational cellular models.
Perturbational omics and translational cellular models: They test the gene’s role in driving cellular phenotype of disease by using a range of perturbation technologies to run interventional experiments. For their high-performance experiments, they are utilising their cellular and pre-clinical models to translate phenotypes.
High-performance experimentation and computation: At their lab, they pull together tissue profiling, single-cell and spatial transcriptomics, sequencing and target validation for drug target discovery and development. Through their partnership with NVIDIA, they are taking advantage of hyperscale compute for their machine learning platforms.
Machine learning: They use machine learning methods, like generative language models and graph neural networks, for target identification, prioritisation, validation, and experimental design.

With their approach, they are uncovering transformational medicines, starting with ones able to address bone-related diseases. At this moment in time, they are using the insights generated by their technology and data to speed-up the advancement of their programmes in bone disease, such as their proprietary functional single-cell atlas Osteomics.

At the end of 2025, Relation announced further investment of $26m so that they can continue their work using their unique approach of combining computation, experimentation, and patient data to reduce failure rates in drug development and completely change the way in which common, yet devastating diseases are treated. For this investment, investors included NVentures, DCVC, and Magnetic Ventures.

Around the same time, they revealed that they have entered into a strategic collaboration with Novartis, an innovative medicines company. The goal of the collaboration is to identify, validate, and advance candidates for first-in-class targets in atopic diseases driven by immune dysregulation through the combination of Relation’s AI-powered drug discovery platform and human data generation capabilities, and Novartis’s deep expertise in immuno-dermatology. As per the agreement, $55m will be given to Relation, broken down into an upfront payment, equity investment, and further R&D funding. They will also be eligible to receive preclinical, development, regulatory, and commercial sales milestones of up to $1.7 billion as well as tiered royalties on net sales of products.

At the start of this year, they announced a new research collaboration with Deerfield Management, a healthcare investment firm. The goal of this collaboration is to advance therapeutic discovery projects for diseases of high unmet need. Targets can be nominated by Relation that have been discovered using their platform for downstream development via a jointly owned NewCo. Together with Deerfield Management, they will develop target product profiles with Deerfield Management also providing due diligence support and drug development plans that must be mutually agreed upon by both parties. They both will receive royalties from the net sales of any future products.

AviadoBio

Evolution: Venture

Fundraising:

£12m equity investment in 2020 for a 63% stake. Investors included Advent Life Sciences, Dementia Discovery Fund (DDF), F-Prime Capital Partners, Johnson & Johnson Innovation (JJDC), and LifeArc Ventures.
£14.9m equity investment in 2021 for a 41% stake. Investors included Advent Life Sciences, DDF, EQT Life Sciences, F-Prime Capital Partners, Johnson & Johnson Innovation (JJDC), LifeArc Ventures, Monograph Capital, and New Enterprise Associates (NEA).
£18.6m equity investment in 2022 for a 34% stake.
£26m equity investment in 2023 for a 32% stake.
£24.1m equity investment in 2024 for a 17% stake. Investors included Astellas Venture Management.
£1.81m equity investment in 2026 for a 1% stake.

Industries: Biotechnology, Clinical research, Pharmaceuticals

Buzzwords: Genomics, Life sciences, Professional and business services, Regenerative medicine

Formed based on pioneering research from King’s College London and the UK Dementia Research Institute, AviadoBio are on a mission to create medicines, from the development and translation of science and precision delivery, that can address neurodegenerative diseases, such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). They are focusing on ways to maximise biodistribution to the neuronal tissue across the brain and eyes, such as through gene therapy and precision delivery.

Included in their founding team of three is Professor Chris Shaw, a trained Neurologist who is the Director of the Maurice Wohl Clinical Neuroscience Institute, and Centre Director of the UK Dementia Research Institute at King’s. He runs an ALS clinic at King’s College Hospital where he leads clinical trials of antisense oligonucleotide therapies. Joining him is Youn Bok Lee, whose career of researching the molecular biology of neurodegenerative disease has spanned over 25 years. A notable discovery of his is the toxic gain of G4C2 RNA repeat expansion function. At King’s College London, he has established his gene therapy group and has conducted pre-clinical research for ALS/FTD. The last founder is Do Young Lee, who has over 15 years of experience in the clinical translation of gene therapies. She joined Freeline Therapeutics in 2015 to lead their research vector core and early preclinical programme designs. She would move on in 2018 to the Department of Basic and Clinical Neuroscience at King’s College London to lead their UK-DRI vector core facility.

AviadoBio are building upon extensive neuroscience expertise to develop targeted, one-time gene therapies capable of precisely delivering genetic medicines to disease-relevant cells and pathways within the nervous system, helping to restore function. Their pipeline covers FTD, retinal dystrophies such as retinitis pigmentosa and geographic atrophy, tauopathies like Alzheimer’s disease, and ALS. To this end, they have focused their precision platforms on three main areas:

Blood-brain barrier (BBB)-penetrant delivery approaches, such as intrathalamic, intravitreal, and intravenous routes of administration.

Engineered AAV vectors made specifically for durable therapeutic expression across complex neural systems, like the brain and retina.

vMiX™ RNA silencing system, which allows for targeted RNA modulation of gain-of-function targets and disease pathways.

Their approach follows a three-step method:

Target: Drivers of neuronal degeneration (CNS and retina) that have great unmet medical need and burden are validated and selected.
Payload: Gene supplementation and gene silencing payloads are engineered to have cell- and tissue-selective regulatory control.
Delivery: Combing capsid innovation with fit-for-purpose routes of administration, they optimise biodistribution, safety, and efficacy of each program.

The lead program of AviadoBio is AVB-101, an investigational gene therapy for those living with FTD with GRN mutations (FTD-GRN), which is currently in Phase 1/2 clinical trial in the UK, Europe, the USA, and Canada. It is administered into the thalamus, an ‘information relay hub’ located in the middle of the brain that receives sensory and motor information from the body, through a minimally invasive neurosurgical procedure. During this process, AVB-101 delivers a working copy of the GRN gene to thalamic neurons, which passes along instructions to the neurons for progranulin production so that the levels of it can be increased throughout the brain. By doing this, it is hoped that they can restore physiological function to patients with FTD caused by progranulin mutations.

Announced earlier last year at the Association for Frontotemporal Degeneration (AFTD) annual caregiver conference was the completion of the second dose cohort in its Phase 1/2 ASPIRE-FTD clinical trial. The purpose of the trail is to evaluate multiple doses of AviadoBio’s AVB-101 in people who are living with FTD and have the GRN gene mutations. At the time of the announcement, they had opened recruitment for participants across multiple sites in countries like the U.S., Spain, Poland, Sweden, and the Netherlands. Around the same time, the trial opened in the UK with patient recruitment happening at the Cambridge University Hospitals NHS Foundation Trust (CUH) and the University College London (UCL). In addition, the Advanced Neurotherapies Centre at Cardiff and Vale University Health Board announced that they would be providing the capability to dose clinical trial participants from the UK and beyond in this study.

Later in the same year, they entered an exclusive option and license agreement with UgeneX Therapeutics, the company behind an innovative ophthalmic gene therapy technology platform and an internationally leading pipeline, for the development and commercialisation of an AAV-based gene therapy, UGX-202. The therapy helps to re-establish vision for patients with retinal diseases by employing visual optogenetics to deliver a light-sensitive protein to cells in the retina. As per the agreement, on offer to AviadoBio is the option to have a global exclusive licence for outside Greater China that gifts the right to develop and commercialise UGX-202 in RP and other indications. If taken, UgeneX in return will receive upfront payments, research and development milestones, and sales milestone payments of up to $413m, in addition to royalties on net sales.

In the first quarter of this year, they started the enrolment for the fourth cohort of their Phase 1/2 ASPIRE-FTD clinical trial. At this time, they have 20 active trial sites across the UK, US, Canda, and six other European countries. Current data shows that there are dose dependent elevations in the key biomarker of cerebrospinal fluid (CSF) progranulin. Positively, the safety profile of AVB-101 remains favourable, with there being no serious adverse events to date. In support of the trials, AviadoBio has received an investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) through the Treat FTD Fund.

AviadoBio announced recently a licensing agreement for Apertura Gene Therapy’s (Apertura) TfR1 CapX™. Apertua are a biotech company who are developing the next generation of AAV capsids capable of delivering genetic medicines. Their TfR1 CapX™ is a novel, intravenously delivered AAV capsid made to target human transferrin receptor 1 (hTfR1), transverse the blood-brain barrier, and allow for the broad distribution to the brain and spinal cord. This AAV capsid will be utilised by AviadoBio to fuel the development of their pipeline of genetic medicines, including AVB-406 which is a preclinical stage gene therapy for Alzheimer’s disease and other tauopathies.

Trogenix

Evolution: Seed

Fundraising:

£12.5m equity investment in 2024 for a 68% stake.
£18.2m equity investment in 2025 for a 37% stake. Investors included 4BIO Capital, Brain Tumor Investment Fund, Calculus Capital, Cancer Research Horizons Seed Fund, Eli Lilly & Co, IQ Capital Fund, LongeVC, and Meltwind Advisory.

Grants:

£767k grant awarded in 2024 by Innovate UK.

Industries: Biotechnology, Clinical research, Pharmaceuticals

Buzzwords: Genomics, Life science, Precision medicine, Regenerative medicine

A University of Edinburgh spin-out, Trogenix utilises Trojan Horse genetic medicines to develop selective treatments for cancer cells without comprising the healthy tissue. They were founded by a team of world-renowned experts in 2023 with the mission of transforming cancer treatment paradigms. Included in this team is their CSO Professor Steve Pollard, a recognised world leader in steam cell and cancer biology. Alongside his work at the University of Edinburgh’s Institute for Regeneration and Repair as a Professor of Stem Cell and Cancer Biology, he is the Director of the CRUK Brain Cancer Centre of Excellence and Associate Director of the CRUK Scotland Centre. He was joined by Dr. Ken Macnamara (CEO). With his experience in the biotech and biopharma industries, he had led his teams in successfully pioneering precision genetic medicines focused at neuromuscular, ocular, auditory, cardiovascular, metabolic, renal, and the central nervous system.

Trogenix’s viral immunotherapy technology uses highly specific Synthetic Super-Enhancers (SSEs), which are engineered DNA elements that act as docking stations for transcription factors uniquely expressed in aggressive cancer or diseased cells. Their SSEs only activate in aggressive cancer cells and are capable of controlling the expression of two therapeutic payloads within an AAV vector system. The payloads work simultaneously, with one producing an enzyme that converts an oral prodrug into a cytotoxic agent and the other generating IL-12 to stimulate an immune response against the tumour. Through the AAV vector, the Trojan Horse, the therapy is injected directly into the tumour. The treatment not only eliminates the primary tumour, it also establishes long-term immune memory so that the tumour cannot re-grow.

Built upon this technology is their three-pronged attack on cancer. The first step is killing cancer cells precisely by using cytotoxic payload. The next step is immune activation, where a ‘hot’ tumour microenvironment is created alongside immunological memory. The final step is using the Trojan Horse Mechanism to guard against tumour plasticity and escape. Their approach has the potential to be a ‘one and done’ curative approach. It could provide long-term protection against regrowth and recurrence, be a personalised immune-therapy, and has the potential to be a treatment for multiple cancer types.

Their main platform is Odysseus, which allows them to identify key transcription factors and design appropriate enhancer fragments for SSE construction through a combination of advanced genomics, profiling, bioinformatics, and machine learning. The platform allows for both the design and validation of SSEs for any human cell type or disease state.

Their leading programme is in glioblastoma (GBM), an extremely aggressive form of brain cancer that affects approximately 200,000 people worldwide. Only about 25% of people with this cancer will survive more than a year and it has a median overall survival of just 15 months. By building upon decades of intensive research, they now have the advanced tools and understanding needed to find a treatment. The GBM therapy they have developed has already shown curative potential in preclinical studies through its complete responses with no toxicity and no relapse, immune responses that are potent innate and adaptive, persistent anti-tumour immunity, efficacy in late-stage tumours, and validation of transduction and expression in patient tumour tissue.

In the middle of last year, they announced that they were awarded Startup of the Year at the 2025 Innovation & Entrepreneurship Awards hosted by Cancer Research Horizons. This award recognises UK-based start-ups who have raised their first funding round within the past two years and are rapidly advancing scientific breakthroughs to deliver new treatments, diagnostics or medical devices specifically for people dealing with cancer. For Trogenix, this award is in recognition of their mission to revolutionise cancer treatment with their Odysseus platform and of the dedication and scientific excellence their team displays.

Nearer the end of the year, they completed their Series A financing with a total of £70m raised. The round was led by IQ Capital, who were joined by 4BIO Capital, Cancer Research Horizons, the Brain Tumor Investment Fund, Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. For Cancer Research Horizons, this is their largest investment to-date. The purpose of the funding is to facilitate the rapid advancement of Trogenix’s pipeline of potentially curative cancer therapies across multiple aggressive solid tumours into the clinic.

Recently, they published in Nature their breakthrough pre-clinical data that reports a complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM). Authored by scientists from the University of Edinburgh, UCL Cancer Institute, and The Royal Infirmary of Edinburgh, the research showed that when SSEs are delivered as a single treatment dose:

It leads to the striking of Tumour regression within one to two weeks, with complete tumour clearance in 83% of treated cases over the following two to three weeks.
It activates precision immunity to eradicate tumours.
There is no more tumour regrowth after the initial treatment. The following 11 months also shows no toxicity.
There is no detectable tumour formation, including after re-challenge.

This research study was funded by Cancer Research UK and the Biotechnology and Biological Sciences Research Council (BBSRC). It is expected that the first clinical trial for glioblastoma will begin in the second quarter of this year.

Resurrect Bio

Evolution: Venture

Fundraising:

£125k equity investment in 2022 for a 21% stake.
£1.61m equity investment in 2023 for a 33% stake. Investors included AgFunder, SHAKE Climate Change Programme, SynBioVen, and UK Innovation & Science Seed Fund (UKI2S).
£7.81m equity investment in 2026 for a 48% stake. Investors included AgFunder, Calculus Capital, Corteva Catalyst, Pymwymic (Put Your Money Where Your Meaning Is Community), SynBioVen, and UK Innovation & Science Seed Fund (UKI2S).

Grants:

£50k grant awarded in 2023 by Innovate UK.
£70k grant awarded in 2024 by Innovate UK.
£44.9k grant awarded in 2024 by Innovate UK.
£99.2k grant awarded in 2025 by Innovate UK.

Industries: Agriculture, land farming and forestry, Biotechnology

Buzzwords: AgriTech, CleanTech, Genomics, Life sciences

London-based Resurrect Bio are on a mission to equip crops with the tools they need to defend themselves through their Resurrects R-genes technology. They were founded by a team of three in 2021. Dr Cian Duggan (CEO), who is leading the company in its innovative research, completed his PhD on how plants try to defend themselves against diseases by researching the molecular mechanisms behind plant immunity at Imperial College London. Professor Tolga Bozkurt (Director) is both a Senior Scientist and Associate Professor at Imperial College London, he has a focus on molecular plant immunology, disease resistance, and host-pathogen interaction. They were joined by Professor Sophien Kamoun. Previous head of The Sainsbury Laboratory, he now works there as the senior scientist alongside his work at the University of East Anglia, where he is a biology professor.

Their technology is based on breaking the interaction between pathogens and crops. Pathogens can cause crops to catch diseases by suppressing the immune response of the crop. By breaking this interaction, they resurrect the crop’s immune system and lock the pathogen out. With this premise, they have built their company upon three pillars:

FloraFold: As their proprietary protein-protein AI prediction tool, it has been trained to accurately predict potential hits on plant to pathogen interactions.
Rapid In-Planta Screening: It quickly screens potential hits from FloraFold, allowing for Resurrect Bio to get targets 10x faster than traditional methods.
Resurrection technology: When applied to targets, it restores immunity and locks out both pests and pathogens.

Their way of work allows them to interact with nearly any combination of crop, pathogen, and pest.

Earlier this year, Resurrect Bio made an initial close in their Series A financing round of over $8m. The investors of the round include Corteva Agriscience, Calculus Capital, Pymwymic, UK Innovation & Science Seed Fund, SynBioVen, and AgFunder. The funding will be used to increase production of their in-house crop protection traits and to further improve their FloraFold platform.

Also announced this year is their partnership with Corteva Agriscience, a global pure-play agriculture company. By combining the outputs of Resurrect Bio’s FloraFold platform with their own Genlytix™ ecosystem and world class genetics resources, they will work together to find solutions to some of the most economically devastating diseases that currently affect US corn production.

AlveoGene

Evolution: Seed

Fundraising:

£2.6m equity investment in 2023 for a 34% stake. Investors included Harrington Discovery Institute, Old College Capital (OCC Ventures), and Oxford Science Enterprises.
£850k equity investment in 2025 for a 10% stake.

Industries: Pharmaceuticals, Research tools and reagents, Surgeries and non-surgical procedures

Buzzwords: Genomics, Life sciences

AlveoGene is on a mission to help create a world where rare respiratory diseases do not prevent vibrant living through the use of inhaled gene therapy. They were formed in 2023 through a joint venture consisting of the Oxford Science Enterprises (OSE), Harrington Discovery Institute at University Hospitals (Harrington), Old College Capital (OCC), who are the University of Edinburgh’s venture investment fund, and six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC). Founded in 2001 through the partnership of Imperial College London, University of Oxford, and the University of Edinburgh, the GTC is applying pioneering research to the development of gene therapies and manufacturing processes related to cystic fibrosis and other respiratory diseases.

Their pipeline is built upon InGenuiTy™, a proprietary and validated next-generation lentiviral delivery platform developed by GTC, for which AlvenoGene has an exclusive licence to. It develops gene therapies for the treatment of respiratory diseases with high unmet need that can be delivered through a nebuliser for a wide range of age groups or by direct instillation with the use of endotracheal tubing for neonates.

Currently in their pipeline, they have four products at various developmental stages:

AVG-002: This treatment, which has been accelerated to clinical trials, is aimed at Surfactant Protein B Deficiency (SP-B), a deficiency caused by inherited mutations in the SP-B gene on chromosome 2. In infants, it leads to respiratory distress and failure that presents shortly after birth, which resists assisted ventilation and short-term synthetic surfactant replacement therapy, and typically means that the infant is unlikely to survive beyond the first few months of their life. A single instilled administration of AVG-002 has the potential to be a viable treatment option and a potential functional cure by turning on the life-long local production of surfactant in the neonatal lung. At this time, it has been awarded Paediatric Rare Disease Designation by the FDA and Orphan Drug Status.
AVG-003: A potential lifelong solution for Surfactant Protein Deficiency (ABCA3), which is an autosomal recessive condition, caused by inherited mutations in the ABCA3 gene on chromosome 16. This results in the loss or defective function of the phospholipid transporter required to produce pulmonary surfactant. The treatment, which has been accelerated to clinical trials, utilises the proprietary lentiviral vector backbone, used by all AlveoGene products, in the delivery of the relevant transgene to the lung.
AVG-001: A novel, inhaled gene therapy for the treatment of AATD (Alpha-1 Antitrypsin Deficiency) lung disease by promoting long term localised production of alpha-1 antitrypsin in the lung. AATD is a rare, inherited disorder that causes patients to produce reduced levels of alpha-1 antitrypsin, which is a protective plasma protein capable of safeguarding the lungs from inflammation and tissue damage due to infection and inhaled irritants. Currently, there is no available cure and the standard of care for this disease is either symptomatic treatment or weekly IV infusions of human plasma-derived functional alpha-1 antitrypsin (only available in some countries). AlvenoGene is hoping to progress this candidate towards clinical development over the next few years.
AVG-004: Aimed at transforming the current treatment paradigm for Idiopathic Pulmonary Fibrosis (IPF), it is made up of two or more transgenes in the same vector backbone and delivered simultaneously to the site of action in the lung. The goal is to extent the patient’s lifespan and improve their quality of life through slowing the progression of the disease and helping to improve the lung function. AlvenoGene’s preferred candidate is being triaged and evaluated in a range of in-vitro and ex-vivo models.

Over the past year, they have released company updates. Of note is that the first calendar quarter of 2025 saw them make promising progress in creating pre-clinical data sets needed for their development programs in Surfactant Protein Deficiencies SP-B and ABCA3, AATD Lung Disease, and IPF. At the end of the year, the revealed that they had successfully generated pre-clinical data in SP-B surfactant protein deficiency (AVG-002), were progressing data for the ABCA3 surfactant protein deficiency, and that data for AATD-Lung disease (AVG-001) supports a future market leading product. Earlier this year, they announced their intention to submit AVG-003 data to the FDA for consideration of obtaining PRDD and ODD status.

Biocentis

Evolution: Venture

Fundraising:

£833k equity investment in 2022 for a 41% stake.
£9.56m equity investment in 2025 for a 66% stake. Investors included Algebris Investments, CORBITES, Neurone, Novaterra, The Grantham Foundation for the Protection of the Environment, and Business Angels.

Grants:

£4.51m grant awarded in 2025 by the Wellcome Trust.

Industries: Biotechnology

Buzzwords: Genomics, Life sciences

Shaping the future of insect control is Biocentis, a life science company who spun out of Imperial College London. They have teams in both the UK and Italy consisting of experts who have built companies valued at billions, created CRISPR (clustered regularly interspaced short palindromic repeats) technologies, and worked to deliver advanced insect control solutions.

Biocentis was founded by a team of five. Teodoro D’Ambrosio (Director), a serial entrepreneur with over 20 years of experience, has founded several ventures whose combined value exceeds €3 billion and has secured funding exceeding €500 million for his co-founded companies. Giorgio Rocca, a trained mechanical engineer, previously worked at Boston Consulting Group as a strategy consultant where he was an advisor to leading companies in both the healthcare and life sciences sectors. Andrew Hammond, an award-winning molecular biologist, is the one behind the research that fed into the development of the most advanced suppression gene drive system which is now the foundation of Biocentis’ IP portfolio. Federico Guelpa previously worked at Oliver Wyman as a strategy consultant, where he was an advisor of strategy and innovation to some of the largest corporations in both Europe and the world. Kyros Kyrou, an expert in genetic control who used to develop genetic control solutions for Target Malaria, was one of the inventors on the suppression gene drive system.

The basis of the technology Biocentis develops is that the release of insects from the target species can be used to reduce the size of the wild population through introducing mating genetic traits associated with reducing fertility. As these traits are self-limiting, they will only be present for a limited number of insect generations. Their process follows four steps:

They start by introducing a specific modification into the genome of male insects from the species being targeted for control.
The males are released into the environment, where they will look for females to mate with. These insects will neither bite nor lay eggs.
Any female offspring will not reach adulthood resulting in the reduction of the harmful insect population. On the other hand, any male offspring will inherit the genetic modification, ensuring that the work can continue. As the modification is self-limiting, it will last for a limited number of subsequent generations.
This intervention results in a strong reduction in the population of the harmful insect. The modification will gradually disappear from the environment if the releases are interrupted.

Their portfolio currently contains solutions that are aimed at a mosquito responsible for transmitting human diseases, including dengue, Zika, yellow fever, and chikungunya, as well as a highly invasive fruit fly threatening global fruit production.

Announced at the end of last year was their funding round which raised $19m. Part of this funding came from a seed equity investment of $13m which was led by The Grantham Foundation for the Protection of the Environment and Algebris Investments. Other investors for the round were Neurone, Corbites, Novaterra, and a network of visionary entrepreneurs, including the founders of two European tech unicorns. Joining this round was a $6m award from Wellcome, a leading global health foundation. The funding will be used to advance Biocentis’ mission of battling the growing global threats posed by insects to health, agriculture, and biodiversity. They will be focusing on advancing their first solutions to field trials across key markets, like the US and Brazil, alongside their work in expanding their technology platforms for new applications.

Price Bailey have extensive experience in the Genomics industry. Our specialisms include auditing, managing complex domestic and international tax affairs, R&D, share incentives, valuations, fundraising, and providing hands on accounting support. Should you wish to discuss any of your needs with us, please contact us using the form below.

We always recommend that you seek advice from a suitably qualified adviser before taking any action. The information in this article only serves as a guide and no responsibility for loss occasioned by any person acting or refraining from action as a result of this material can be accepted by the authors or the firm.

Sign up to receive exclusive business insights

Join our community of industry leaders and receive exclusive reports, early event access, and expert advice to stay ahead – all delivered straight to your inbox.